Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 14 August 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In the renewable energy business, the company recognized a valuation loss on advances paid because it revised its business plan, which had assumed lump-sum sales, and adopted a policy of combining development, sale, holding and conversion to battery storage facilities on a property-by-property basis. In the wholesale business, an impairment loss related to the Cure brand, upfront costs and a temporary decline in inbound demand were incurred, while in the retail business, revenue and profit were deferred due to costs associated with business-format conversions, temporary closures and other factors.
Valuation loss on advances paid: ¥983.964 million; goodwill and customer-related assets related to the Cure brand: ¥53.429 million; tools, equipment and fixtures: ¥7.668 million; total impairment losses: ¥61.098 million. Total extraordinary losses: ¥1,045.062 million.
| Item | Details |
|---|---|
| Net Sales | ¥2,145 million → ¥2,232 million（+4.1%） |
| Operating profit | ¥-482 million → ¥-557 million |
| Ordinary income | ¥-549 million → ¥-635 million |
| Profit attributable to owners of the parent | ¥-596 million → ¥-1,693 million |
| Net income per share | ¥-49.28 / sen → ¥-136.97 / sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 August 2026 |
| Previous-period results | Fiscal year ended September 2025: Revenue ¥2,441 million, operating loss ¥165 million, ordinary loss ¥206 million, net loss attributable to owners of the parent ¥243 million, basic loss per share ¥23.64 |
| Reason for the revision | In the renewable energy business, the company recognized a valuation loss on advances paid because it revised its business plan, which had assumed lump-sum sales, and adopted a policy of combining development, sale, holding and conversion to battery storage facilities on a property-by-property basis. In the wholesale business, an impairment loss related to the Cure brand, upfront costs and a temporary decline in inbound demand were incurred, while in the retail business, revenue and profit were deferred due to costs associated with business-format conversions, temporary closures and other factors. |
| Details and amount of extraordinary loss | Valuation loss on advances paid: ¥983.964 million; goodwill and customer-related assets related to the Cure brand: ¥53.429 million; tools, equipment and fixtures: ¥7.668 million; total impairment losses: ¥61.098 million. Total extraordinary losses: ¥1,045.062 million. |
| Consolidated / non-consolidated | Consolidated / non-consolidated (standalone) |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reasons cited include a valuation loss on advances paid following a review of the monetization policy for solar power plants and other assets, an impairment loss related to the Cure brand, a temporary decline in inbound demand, and costs associated with business-format conversions, including renovation, advertising and sales promotion expenses and store-closing costs.